Last reviewed · How we verify
NCT04937361: R-Net
Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network
trial testing rectal swab in MDRO in 12,000 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | University of Luebeck |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 12,000 |
| Start date | 23 June 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- rectal swab — full drug profile →
Conditions studied
- MDRO — all drugs for MDRO →
Sponsor
University of Luebeck
Who can join
18 and older, any sex, with MDRO. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Survey on the prevalence of MDRO to monitor the import of MDRO from the community. Rectal swabs will be taken and cultivated. Survey on community-onset and nosocomial bloodstream infections will be documented and strains will be isolated. For each BSI a clinical data set will be obtained (e.g. patient age, gender, date of hospitalization, antibiotic therapy). Genetic analysis of MDRO from the prevalence and BSI study. In a subset of patients the microbiome-resistome interactome will be analysed in more detail. Furthermore, the impact of infection control measures due to the Covid-19 pandemic on nosocomial BSI will be investigated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Towards unraveling antimicrobial resistance dynamics: a longitudinal exploration of rectal swab metagenomes.
Boutin S, Käding N, Belheouane M, Merker M, et al · · 2025 · cited 1× · PMID 40097931 · DOI 10.1186/s12866-025-03874-z
Verify or expand the search:
- PubMed search for NCT04937361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of rectal swab
Trials testing the same drug.
- NCT04355533 — Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19 · NA · completed
- NCT03248999 — Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes. · NA · completed
- NCT02928367 — The Effect of Leukocyte Dna mEthylation and micRoBIOME Diversity on Host Defense Mechanisms During Community-acquired Pn · unknown
Other University of Luebeck trials
Trials by the same sponsor.
- NCT06598280 — Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation · NA · recruiting
- NCT06493994 — Myval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry · recruiting
- NCT05846412 — Treatment of Functional Mitral Regurgitation in Patients With Atrial Fibrillation · NA · unknown
- NCT05710822 — QDOT Based PVI for Atrial Fibrillation Treatment - The peQasus Study · unknown
- NCT05563142 — Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04937361 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Luebeck
- Last refreshed: 29 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04937361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing